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Autophagy is best known as a lysosomal degradation and recycling pathway to main-
tain cellular homeostasis. During autophagy, cytoplasmic content is recognized and 
packed in autophagic vacuoles, or autophagosomes, and targeted for degradation. 
However, during the last years, it has become evident that the role of autophagy is not 
restricted to degradation alone but also mediates unconventional forms of secretion. 
Furthermore, cells with defects in autophagy apparently are able to reroute their cargo, 
like mitochondria, to the extracellular environment; effects that contribute to an array 
of pathologies. In this review, we discuss the current knowledge of the physiological 
roles of autophagy-dependent secretion, i.e., the effect on inflammation and insulin/
hormone secretion. Finally, we focus on the effects of autophagy-dependent secretion 
on the tumor microenvironment (TME) and tumor progression. The autophagy-mediated 
secreted factors may stimulate cellular proliferation via auto- and paracrine signaling. 
The autophagy-mediated release of immune modulating proteins changes the immuno-
suppresive TME and may promote an invasive phenotype. These effects may be either 
direct or indirect through facilitating formation of the mobilized vesicle, aid in anterograde 
trafficking, or alterations in homeostasis and/or autonomous cell signaling.
Keywords: autophagy, secretion, autosecretion, tumor progression, tumor microenvironment, unconventional 
secretion
AUTOPHAGY
Autophagy is a catabolic process required to maintain cellular homeostasis by lysosomal degradation 
of aged/damaged organelles (e.g., mitochondria), protein aggregates, and pathogens. Autophagy 
commences with the formation of an initial cup-shaped membrane (phagophore) that elongates 
while (non-) selectively capturing cytoplasmic constituents into a double-membrane vesicle 
(autophagosome). Ultimately, the autophagosome fuses with a hydrolase and protease containing 
lysosome for degradation of the content. The end-products are recycled into the cytosol and are 
reused in processes including protein synthesis and ATP production.
During the last decade, extensive research revealed that at least 38 autophagy-related proteins 
(ATGs) comprise the core autophagy machinery that mediate initiation, elongation, cargo recruit-
ment, and fusion with lysosomes (1). Furthermore, the yeast atg8 orthologs of the LC3/GABARAP 
protein family fulfill specialized roles in the execution of autophagy (2). This family consists of 
seven active members [LC3A (two splicing variants; LC3A-a and LC3A-b), LC3B, LC3C, GABARAP, 
GABARAPL1, and GABARAPL2], which share a high mutual homology, including a conserved 
C-terminal glycine residue for phosphatidylethanolamine (PE) conjugation to allow membrane 
TAble 1 | Autophagy-dependent secreted factors.
Protein Mechanism Reference
Acbp Atg5, Atg7, Atg8, Atg12 (16)
IL-1B ATG5 (11)
NBR1, P62, OPTN, and CACO2 LC3B-II Inhibition or depletion of PIKfyve by apilimod or siRNA (19)
Angiogenin 4, interlectin 1, and relmβ ATG16L1 ATG5 or ATG7 (25)
MUC5AC ATG5 and ATG16L1 (26)
Insulin GABARAP
NPY ATG16L1 as RAB33a effector (33)
von Willebrand factor (vWF), P-selectin, interleukin-8, angiopoietin-2, and endothelin-1 ATG7, ATG5, chloroquine or bafilomycin A1 (34)
Matrix-degrading factors including cathepsin K ATG5 or ATG7 (35)
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association. Conjugation of the LC3/GABARAP protein family 
members to PE is required for expansion and closure of the 
phagophore. This process is controlled by two ubiquitin-like 
conjugation systems, a process closely orchestrated the ATG4, -7, 
and -3 and the ATG12–ATG5–ATG16L1 complex (3).
Despite the high grade of homology, the protein family 
members harbor individual roles in autophagy and are associated 
with autophagy unrelated functions, such as receptor trafficking, 
too (2).
Autophagy (and related defects) is associated with several 
pathologies, including neuropathologies, Crohns disease, and 
cancer. In cancer, autophagy is considered a double-edged sword, 
i.e., in healthy tissue, autophagy plays a cytoprotective role by 
maintaining homeostasis through degradation of cytotoxic 
constituents, which otherwise may trigger tumorigenic events. 
Nevertheless, once a tumor is formed, autophagy contributes to 
survival of cancer cells in areas deprived of nutrients of oxygen 
(hypoxia) (4, 5), a common feature of solid tumors that contrib-
utes to tumor progression, therapy resistance, and metastases 
formation (6).
Yet, accumulating research shows that the homeostatic role of 
autophagy and its related proteins is more elaborate than the deg-
radation of cytoplasmic content alone. Autophagy not only con-
tributes to intracellular homeostasis but also seems to contribute 
to tissue homeostasis by mediating intercellular communication. 
Peptides, proteins, and hormones that fail to enter the conven-
tional secretory system due to the lack of a leader/secretion signal 
sequence can be secreted in an autophagy-dependent manner.
In this review, we list the current knowledge on the role of 
the autophagy machinery in autophagy-dependent secretion and 
specifically focus on factors that may influence tumor progression.
(UN)CONveNTiONAl PROTeiN 
SeCReTiON
In eukaryotes, a classical route for proteins to be secreted is the 
endoplasmic reticulum (ER)-to-Golgi route. Herein, proteins are 
directed toward the ER by their amino terminal signal peptide 
(leader peptide) and progress through vesicular flow to the 
Golgi. In brief, after ER translocation, proteins are oligomerized 
and packed into carrier vesicles that exit the ER at specialized 
regions. These vesicles assemble into vesiculo-tubular structure 
intermediates known as the ER-to-Golgi intermediate compart-
ments (ERGIC) that, by lateral communication, sort proteins 
for further anterograde flow to the Golgi complex. In the Golgi, 
proteins are glycosylated to ensure proper protein structure, 
increase stability, and to allow interactions with target proteins 
(7). In the trans-Golgi network, secretory proteins are sorted 
into secretory vesicles that deliver their content to the plasma 
membrane to result in secretion (8). An increasing number of 
secreted proteins that lack the leader peptide have been identified. 
These proteins require alternative pathways to be secreted in a 
regulated fashion. This implies differences in vesicle formation, 
sorting, and transportation. Multiple alternate, non-classical 
pathways exist and are commonly referred to as unconventional 
protein secretion and include both non-vesicular and vesicular 
mechanisms (9). For example, cytosol-residing proteins, includ-
ing ABC transporter-mediated yeast a-factor (3) or mammalian 
fibroblast growth factor 2 (FGF2) are directly transported across 
the plasma membrane. For FGF2 secretion, this is presumed to be 
mediated through PI(4,5)P2-induced oligomerization followed 
by membrane insertion and translocation (10). Other proteins 
are sorted into vesicular intermediates that fuse with the plasma 
membrane to release their content into the extracellular space 
[interleukin 1β (IL-1β) and IL-18 (11)], in part dependent on 
proteins required for autophagy execution (12, 13). This sug-
gests that autophagy-proteins are required to produce secretory 
vesicles or that autophagosomes gain exocytic features. These 
processes in autophagy-mediated secretion are distinct from its 
degradative compartment [as reviewed in more detail in Ref. 
(14)]. In this context, the trafficking, tethering, docking, and 
plasma membrane fusion events would differ from canonical 
autophagy and resemble exocytic mechanisms. Herein, secretory 
vesicles are diverted from the endocytic system to be released 
from multivesiclular bodies (MVB). These secretory vesicles are 
then transported to the plasma membrane for content release. 
For example, the interaction between autophagosomes and the 
endocytic/MVB pathway [reviewed in Ref. (15)] is required for 
acetyl-CoA-binding protein (Acb1)-secretion and requires the 
fusion of Acb1-containing autophagosomes with endosomes or 
MVBs before plasma membrane fusion (16).
The involvement of autophagy-related proteins, in protein 
secretion indicates that cells utilize these effectors in a surprising 
mechanism of unconventional secretion. Here, we will discuss 
the data that support a relation between autophagy or autophagy-
related proteins with secretory pathways (Table 1). First, we will 
elaborate on the physiological roles of autophagy in secretory 
events. Second, cancer cells utilize secretory mechanisms to 
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communicate with stroma and surrounding cancer cells, thereby 
inducing alterations that influence tumor progression, includ-
ing immunoevasion, immunesuppression, auto- and paracrine 
signaling, and angiogenesis.
PHYSiOlOGiCAl ROleS OF 
AUTOPHAGY-MeDiATeD SeCReTiON
The first evidence for the involvement of autophagy-related pro-
teins in protein secretion was obtained in yeast. Acyl coenzyme 
A-binding protein (Acbp) is secreted through an unconventional 
secretory pathway that depends on components of the autophagic 
process (Atg5, Atg7, Atg8, Atg12) (16). Importantly, this study 
also demonstrated that autophagy connects with compartments 
(multivesicular bodies) of endosomal trafficking and SNARE-
dependent membrane fusion events are both required for the 
Acbp secretion. Since the discovery of autophagy-dependent 
secretion in yeast, also several mammalian factors have been 
identified to be dependent on autophagy-related proteins for 
their secretion.
Phosphoinositides are membrane lipids with specific recog-
nition domains for the recruitment of cytosolic proteins and 
are involved in the regulation of membrane transport. So far, 
seven phosphoinositides have been described. They can be 
converted into each other by phosphoinositide kinases and 
phosphatases (17). PIKfyve is one of those converting kinases 
and has been implicated in membrane transport events. The 
substrate of PIKfyve, PI(3)P, plays a critical role in the initiation 
of autophagy and autophagosome maturation (18). Inhibition 
or depletion of PIKfyve by apilimod or siRNA resulted in 
decreased autophagic flux, probably caused by an impaired 
autophagosome/lysosome fusion. Interestingly, prostate cancer 
cells incubated with the PIKfyve inhibitor apilimod, secrete 
more autophagy-associated proteins (NBR1, P62, OPTN and 
CACO2, and membrane-bound LC3B); however, proteins 
involved in earlier stages of autophagy were not observed 
(ATG2A, ATG5, and ATG16L). Analysis of density gradients 
reveal that these autophagy-associated proteins are expressed 
on vesicles and appear as autophagosome subpopulations, sug-
gesting induced secretory autophagy (19).
Cytokines and inflammation
Autophagy is able to suppress inflammasome activation through 
maintaining mitochondrial homeostasis (20). In line, Zhang et al. 
observed increased inflammasome activation in macrophages 
after sepsis in Gamma (γ)-aminobutyric acid type A receptor 
(GABAAR)-associated protein (GABARAP) knockout mice (20). 
Secretion of cytokines is central in inflammasome activity. Well-
documented cytokines that are associated with unconventional 
secretion in an autophagy-dependent manner are interleukin-1 
beta (IL-1B) and IL-18. Dupont et  al. demonstrated in bone 
marrow-derived macrophages during conditions of induced 
autophagy (starvation or Torkinib treatment) that secretion of 
IL-1B increased, which was reduced in the absence of ATG5. 
Consistent with data obtained from yeast Acbp, similar addi-
tional factors were required [as mammalian equivalents of yeast 
Golgi-associated protein (GRASP55) and small GTPase Rab8a], 
indicating a conserved system or cooperation (11).
Interestingly, three-dimensional STochastic Optical 
Reconstruction Microscopy (STORM) demonstrated that IL-1B 
was not only present in the inner vesicle of the autophagosome 
but was already recruited to the emerging phagophore. In this, 
IL-1B is actively translocated across the membrane and accu-
mulated in the intermembrane space of the mature autophago-
some (21). This, in contrast to the sequestration of degradable 
autophagosomal content which is located in the inner vesicle as a 
result of cytoplasmic engulfment and closure of the phagophore, 
novel mechanism indicates differences in cargo recruitment and 
indicates formation of different vesicles by the autophagy-related 
proteins that may guide the distinct fate of the produced vesicle.
Role of Autophagy-Dependent Secretion 
in establishing a barrier for infection
Paneth cells are specialized epithelial cells present at the base 
of the crypts of Lieberkuhn. These cells control the intestinal 
microbiota through secretion of intracellular granules that con-
tain antimicrobial peptides and lysozyme. Autophagy-proteins 
are essential for Paneth cell function. Knockdown of crucial 
autophagy genes [ATG16L1, ATG5, or ATG7 (22, 23)] result in 
alterations in Paneth cell granules, as illustrated by fewer and 
aberrant granules with diffuse lysozyme patterns and decreased 
presence of lysozyme in mucus. Due to its relevance in establish-
ing a microbial barrier, the ATG16L1 gene was annotated as a 
Crohns disease (CD) risk allele (24) and the phenotype is similar 
to the abnormalities found in Paneth cells of CD patients.
In contrast to CD where the ileum and colon are often affected, 
ulcerative colitis is restricted to the colon only. Conditional 
knockdown of ATG7 in the colon (GlcNAc6ST-2-Cre) increased 
bacterial colonization in crypts. This phenotype was associ-
ated with a decreased release of mucin from goblet cells and 
reduced expression of antimicrobial and antiparasitic peptides 
(angiogenin 4, interlectin 1, and relmβ). Hence, colonic ATG7 
knockdown results in increased susceptibility to the development 
of UC-like colitis (25).
In line with autophagy-dependent secretion by intestinal tis-
sue, ATG5 and ATG16L1 deficiency results in reduced secretion 
of mucins (MUC5AC) by human tracheal epithelial cells (26).
Together, autophagy-dependent secretion is required to 
maintain effective antibacterial barriers by epithelial cells. In 
line, ATG16L1 conditional knockout mice (Villin-Cre) are more 
susceptible to Salmonella typhimurium infection (27). Although, 
beyond the contribution of establishing a barrier function, 
autophagy is required for limiting bacterial proliferation through 
ATG16L1- and LC3C-dependent degradation of cytosol-residing 
Salmonella (xenophagy) (28). Evidently, autophagy is a prereq-
uisite for different cell types to maintain their function (e.g., 
mucus secretion) thereby and protection against inflammatory 
disorders.
insulin Secretion
Pancreatic β-cells are specialized in secretion of insulin in response 
to high levels of blood glucose concentrations. Release of insulin 
4Keulers et al. Autosecretion in Tumor Progression
Frontiers in Oncology | www.frontiersin.org November 2016 | Volume 6 | Article 251
is mediated by the fusion of insulin-containing vesicles with the 
plasma membrane. These insulin-containing vesicles are trans-
ported toward the plasma membrane. GABARAP, one of seven 
mammalian variants of yeast Atg8, which is already known to be 
implicated in multiple cellular functions including fusion events 
in autophagy (29) and receptor trafficking (30), has recently been 
demonstrated to mediate insulin secretion. Herein, GABARAP 
binds insulin-containing vesicles in a PE conjugation-dependent 
mechanism (31). Together with its microtubules-binding feature 
[residues 10–22 (30)], GABARAP allows vesicle presentation to 
the motor protein KIF5B (located at microtubules) and facilitates 
vesicle mobility and insulin release (32).
NPY Secretion
In rat adrenal medullar pheochromocytoma derived cells, the 
neurites display ATG16L at dense-core vesicles. Although these 
vesicles do not co-localize with LC3, release of peptide hormone 
neuropeptide Y (NPY) is dependent on ATG16L1 functioning as 
a Rab33a (which regulates membrane trafficking events) effector. 
Interestingly, NPY secretion was not altered in cells that were 
deficient in autophagy by overexpressing ATG4BC74A or knock-
down of ATG13 or ULK1 and indicates a highly specialized role 
for ATG16L1 in hormone secretion that is independent of other 
canonical autophagy-associated proteins (33).
Autophagy-Mediated Secretion of  
weibel–Palade bodies in vascular 
endothelial Cells
Vascular injury stimulates endothelial cells to secrete factors to 
promote repair. Endothelial secretory granules [Weibel–Palade 
bodies (WPBs)] contain active molecules, including von 
Willebrand factor (vWF), P-selectin, interleukin-8, angiopoie-
tin-2, and endothelin-1. The intracellular WPBs are characterized 
by striations parallel to its longitudinal axis and are delineated by 
a membrane. When secreted, the multimeric hemostatic vWF is 
tethered to the connective tissue to mediate platelet adhesion at 
sites of vascular injury. The processing of vWF to a mature form 
is important in the WPB formation. Treatment with chloroquine 
or bafilomycin A1, both raise lysosomal pH, and knockdown of 
ATG7 or ATG5 reduce the number of endothelial WPBs due to 
incorrect processing of vWF. In line, endothelial specific deletion 
of Atg7 in mice led to reduced epinephrine-induced plasma vWF 
levels and increased bleeding time. Thus, autophagy in endothe-
lial cells aids in hemostasis by proper maturation of WPBs (34).
Osteoclastic bone Resorption
Bone remodeling is a lifelong process of bone degradation and 
formation important for bone healing after injury, bone restruc-
turing, and sustaining bone homeostasis. Osteoclasts cooperate 
with osteoblasts in bone remodeling in which osteoclasts are 
responsible for bone degradation and reabsorption of mineral-
ized bone matrix. The osteoclasts are large multinucleated cells 
that are characterized by their ruffled border by which contact 
area with the bone is increased. Fusion of secretory lysosomes 
with the ruffled border causes release of matrix-degrading  factors 
including cathepsin K which aids bone matrix degradation. 
ATG5- or ATG7-deficient osteoclasts lack a normal ruffled border, 
impaired localization of secretory factors, including cathepsin 
K, and eventually have impaired bone resorption. Importantly, 
development of osteoclasts was not aberrant indicating that the 
autophagy deficiency led to functional impairment independent 
of sustaining cellular homeostasis. Moreover, secretory lysosome 
formation was unaffected, whereas Rab7 (key factor for lysosome 
fusion events) localization to ruffled border was ATG5 dependent. 
Together, these data indicated that autophagy-related proteins aid 
in secretory events at the osteoclast ruffled border by directing 
fusion of the secretory lysosome with the plasma membrane (35).
In conclusion, autophagy is important for secretory functions 
of various cell types. Important to note is that autophagy can have 
either direct or indirect contribution to protein secretion. For 
example, ATGs directly facilitate protein secretion by mediating 
cargo sequestration (as IL-1B) or vesicle trafficking (as insulin), 
but autophagy also maintains cellular homeostasis that is impor-
tant to preserve the specialized function (IL-1B and vWF) and 
primes the plasma membrane for proper release of autophagy-
independent secretory vesicle (as in osteoclasts). Furthermore, 
for sustaining a microbial barrier, autophagy’s contribution is 
dual as both a canonical form of autophagy (xenophagy) and the 
regulation of important secretory factors as mucin contribute to 
prevent pathogen invasion.
SeCReTORY AUTOPHAGY:  
wASTe DiSPOSAl?
Damaged and aggregated proteins and aged organelles are typi-
cally degraded by autophagy. Substrates for autophagy are ubiq-
uitylated and recognized by autophagy receptors and degraded. 
Recent work indicates that defective or saturated autophagy, i.e., 
by defective autophagosome/lysosome fusion results in cargo 
secretion into the extracellular environment.
Lysosomal dysfunction is associated with the secretion of 
aggregation prone proteins that are associated with neuro-
degenerative diseases as Parkinson’s and Alzheimer’s disease. 
α-Synuclein is a presynaptic neuronal protein that is genetically 
and neuropathologically linked to Parkinson’s disease. Wild-type 
α-synuclein is typically degraded by the autophagy and the pro-
teasome (36). Interestingly, tubulin polymerization-promoting 
protein/p25a, expressed in the CNS, sorts α-synuclein into 
autophagsomes but simultaneously prevents its degradation 
through inhibition of autophagosome/lysosome fusion. Instead 
p25a controls α-synuclein clearance by its release in the extracel-
lular environment in an autophagy-dependent manner (37).
Alzheimers’ disease is characterized by the accumulation 
of intracellular Amyloid beta (AB) peptide and tau aggregates 
and extracellular AB plaques. In normal conditions, intracel-
lular proteins are cleared by autophagy and autophagosomes 
are resolved in the process. However, during Alzheimer disease, 
autophagosomes accumulate, indicative of impaired autophagy. 
Autophagy deficiency (ATG7 knockout) in excitatory neurons 
results in intracellular AB accumulation, confirming its role in 
clearance of AB aggregates by autophagy. Although AB increased 
intracellularly, extracellular AB plaque formation was drastically 
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reduced. Reconstitution of ATG7 expression by lentiviral trans-
duction, rescued the secretory phenotype. In parallel, pharmaco-
logic modulation by either induction or inhibition of autophagy, 
by rapamycin or spautin-1, increased and reduced extracellular 
AB release, respectively. Thus, autophagy influences intracellular 
transport and secretion of AB (38).
Mitochondria, the energy producing centers of the cell, 
generate ROS as a byproduct of oxidative phosphorylation. In 
many cancers, ROS production is increased due to mutations in 
mitochondrial DNA, hypoxia, or disturbed metabolism, leading 
to cancer progression (39). The homeostasis of mitochondrial 
ROS plays an important role in the regulation of autophagy. 
Depolarized and ROS leaking mitochondria are typically degraded 
by a selective form of autophagy, mitophagy. In depolarized 
mitochondria, PINK recruits Parkin to mediate selective removal 
of the organelle in a degrative autophagy-dependent manner. 
However, a recent report shows that there is an alternative way 
to maintain mitochondrial homeostasis in the cell. Mesenchymal 
stem cells (MSC) pack depolarized mitochondria in microvesicles 
and release them in the extracellular environment to outsource 
mitophagy where they are recognized by and transferred to 
macrophages. These released microvesicles are highly enriched 
in LC3 and ATG12 compared to whole-cell extracts. This mito-
chondrial transfer probably serves to increase MSC survival (40). 
Similarly, lipopolysaccharide (LPS)-stimulated rat hepatocytes 
secrete mitochondrial proteins CPS1 and COXIV, a component 
of the mitochondrial respiratory chain and associated with the 
inner mitochondrial membrane, and mitophagy-related proteins 
PARK2, and PINK1 and LC3B-II. These effects are inhibited by 
the autophagy inhibitor 3methyladenine or after Atg5 knockout, 
suggesting a role for autophagy in the secretion of mitochondria 
after LPS stimulation (41).
Also endothelial cells are able to release vesicles with 
autophagosome characteristics. During apoptosis, endothelial 
cells release in addition to apoptotic bodies, vesicles in an 
unconventional manner (13). Ultrastructural analysis by electron 
microscopy showed single membrane vesicles up to 10 μm which 
contained structures of mitochondria, multivesicular bodies, and 
autophagosomes. Further proteomic analysis revealed the release 
of autophagy-associated proteins ATG16L1, LAMP2, and LC3B. 
The biological function is of this phenomenon remains to be 
elucidated (12).
The previous section lists the evidence that cells are able to 
release autophagic vesicles into the extracellular environment. 
Vesicle release during defects in the autophagic process, specifi-
cally during autophagosome/lysosome fusion, suggests alterna-
tive mechanisms in waste removal.
eFFeCTS ON THe TUMOR 
MiCROeNviRONMeNT
Regardless of the clinical advances in the past decades that have 
improved cancer patient outcome, cancer is still one of the lead-
ing causes of death in the world. Importantly, the efficacy of treat-
ment strategies is heavily influenced by cancer cell autonomous 
features but also by the tumor microenvironment (TME). Solid 
tumors consist of a variety of cell types, including the cancer cells, 
endothelial cells, immune cells, and fibroblasts and contain well- 
and poorly perfused areas that results in inefficient nutrient and 
oxygen supply (42, 43). Normal (non-transformed) cells in the 
TME are reprogrammed by the cancer cells to their benefit. This is 
exemplified by growth supporting angiogenesis and the suppres-
sion of anti tumor immunity. Importantly, an existing connection 
between autophagy and tumorigenesis has already been estab-
lished. For example, deletion of a single BECN1 allele [Beclin1 
protein important regulator of autophagy (44)] predisposes mice 
to spontaneous tumor development (45, 46). Further, depletion of 
FIP200 (important for autophagy initiation) in mammary cancer 
cells inhibits tumor initiation and progression including metas-
tases (47). Autophagy in cancer cells supports their survival (by 
aiding the high energy demand) and abets resistance to metabolic 
and oxidative stresses (e.g., hypoxia) (4, 48–52). Although this 
role is well established, the contribution of autophagy-related 
intercellular communication that influences tumor progression 
through evasion of immunosurveillance, immunogenic cell death 
(ICD), angiogenesis, and an invasive phenotype is an emerging 
field with great interest. For example, in cancer, the RAS genes 
HRAS and KRAS are frequently mutated. Although the exact role 
of autophagy in tumor progression of RAS-mutated tumors is still 
under debate, autophagy seems to be dispensable for the growth 
and survival of KRAS-mutated cancer cell lines derived from 
human tumors (53). However, when non-RAS-mutated cells are 
transformed with oncogenic RAS, these cells are highly depend-
ent on autophagy for tumorigenic events (54). In addition, the 
invasive phenotype of HRASV12-transformed breast cancer cells 
is reduced in ATG7 knockdown cells. This invasive phenotype 
could be rescued by incubating these autophagy-deficient cells 
with conditioned medium of autophagy-proficient cells. This 
supports an autophagy-dependent secretory system that supports 
tumor progression (55).
In the next section, the current knowledge on proteins secreted 
through autophagy-mediated processes that influence tumor 
progression is discussed (Table 2).
influencing immunogenic Cell Death to 
evade immunosurveillance
Under normal circumstances, immune cells [including dendritic 
cells (DCs), natural killer (NK) cells, and T cells] recognize and 
eliminate newly formed neoplastic cells due to their high immu-
nogenic nature as a result of their mutational burden (immuno-
surveillance). Cancer cells that have obtained an immune evasive 
phenotype are able to circumvent recognition and subsequent 
elimination by the cooperative immune cells. These cancer 
cells are then selected for characteristics that circumvent local 
immunosurveillance and contribute to the growth of the lesion. 
With recent advances, the immune evasive feature is a topic of 
interest for the development of therapeutic strategies. Ideally, 
the elicited cancer therapy-induced cell death should provoke an 
immunogenic chain reaction that includes boosting the immune 
system to tilt the balance toward recognition rather than evasion, 
called ICD. ICD invokes the release of immunomodulatory 
proteins [damage-associated molecular patterns (DAMPs)] that 
TAble 2 | effects on the tumor microenvironment.
Protein(s) Mechanism effect Reference
influencing immunogenic cell death to evade immune surveillance
ATP ATG5 knockdown After radiotherapy and MTX exposure “eat me signal” for immune cells. Stimulus for DC 
recruitment, IFNγ-producing CD4 and CD8 T cells
(60–62)
HMGB1 ATG5fl/fl Promote processing and presentation of tumor antigens by DCs, enhanced immuno 
surveillance
(11)
Cytokine release and influence on the tumor microenvironment
IL1-B, IL-6, IL2 GABARAP Knockout mice Increased secretion by macrophages (78)
IFNγ GABARAP Knockout mice Increased secretion by lymphocytes (78)
CXCL9, CXCL10, 
and CXCL11
FIP200 conditional knockout Enhanced secretion, leading to improved immuno surveillance (47)
Prometastatic: driving an invasive behavior of cancer cells
LIF, FAMC3, DKK3, 
IL-8
ATG7 knockdown These factor promote metastasis via MMP2 upregulation (IL-8), epithelial to mesenchymal 
transition (FAM3C, DKK3, LIF), and promotion of angiogenesis (IL-8 and DKK3)
(80)
ATG7, ATG12, ATG3 knockdown 
chloroquine or bafilomycin A1
Autophagy-deficient HRASV12-transformed breast cancer cell lines display reduced invasive 
protrusions. Conditioned medium of autophagy-proficient cells rescued the invasive 
phenotype
(79)
IL6, CCL-2, CCL-20, 
VEGFA, MMP2
3-MA, ATG5, and ATG7 
knockdown
TLR3 and TLR4 activation leads to autophagy-dependent secretion of these factors 
associated with a migratory and invasive phenotype of lung cancer cells
(82)
IL6 ATG7 or beclin knockdown Autophagy deficiency lead to an increase or decrease in low or high autophagic breast 
cancer cells, respectively. Autophagy-dependent secretion of IL-6 are able to promote 
mammosphere formation and may be important in CSC maintenance
(83, 84)
Prometastatic: proper weibel–Palade body formation in vascular endothelium to facilitate metastasis




HMGB1 HMGB1 causes doxorubicin resistance in neighboring breast cancer cells (88)
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incite antitumor immunity (56). ICD can be induced by selective 
chemotherapeutics, including mitoxantrone (MTX) and oxalipl-
atin (OXA) and radiotherapy [reviewed in Ref. (57)]. Cancer cells 
undergoing ICD stimulate and activate the innate immune cells. 
Subsequently, this can result in the cross-priming of the adaptive 
immune system for the antigens of dying cancer cells, thereby 
leading to an effective activation of antitumor immunity. This 
can elicit a long-term therapeutic effect (even after therapy has 
stopped) and is fundamental to observed abscopal effects. In line, 
clinical studies have demonstrated that lymphopenia negatively 
affects chemotherapeutic response of solid tumors (58) and that 
ICD-associated DAMPs can be used as predictive and prognostic 
biomarkers (59).
Important immunogenic DAMPs that are displayed by cells 
undergoing ICD are secretion of ATP, surface exposure of cal-
reticulin (CRT), release of heat shock proteins, and high mobility 
group box 1 (HMGB1). Interestingly, ATG5 knockdown in colon 
cancer cells reduces ATP release after radiotherapy (60) and MTX 
exposure (61), which was associated with a decreased effect on 
tumor growth inhibition. Interestingly, in autophagy-deficient 
cells, no differences in CRT surface exposure or HMGB1 release 
were observed (61). The relevance of autophagy-dependent 
radiotherapy-induced ATP release was further supported by the 
observation that treatment with an inhibitor of ecto-ATPase only 
increased radiosensitivity in immunocompetent but not immu-
nodeficient mice. Here, a partial rescue of lymphocyte infiltration 
indicates that the autophagy-dependent radiotherapy-induced 
ATP release enhances antitumor immunity (60). Similarly, for 
MTX treatment of osteosarcoma cells, it was also shown that 
ATG5 is required for ATP secretion. Interestingly, on a more 
mechanistic level, Martins et al. demonstrated that ATP (stored 
in lysosomes) is released upon MTX and OXA treatment and 
is associated with LAMP1 (lysosomal marker) translocation 
to the plasma membrane. Nonetheless, a role for autophagy 
seems to be maintaining an intracellular ATP pool (may even 
be cargo sequestration) required for (LAMP1+) lysosome-
dependent ATP release. Accordingly, the replenishment of ATP 
to lysosomes was reduced when autophagy genes were knocked 
down (62). ATP release conveys an important “eat me” signal for 
immune cells. Once it is released, ATP may attract innate effector 
cells of the immune system into the tumor bed. Consistently, it 
was demonstrated that autophagy-dependent ATP release from 
MTX-treated colon cancers was a stimulus for DC recruitment, 
IFNγ-producing CD4 and CD8 T cells that had favorable effects 
on MTX sensitivity (61). Correspondingly, ATG7 in a geneti-
cally induced melanoma mouse model was required for MTX-
dependent growth inhibition that was reliant on functional CD4 
and CD8 T cells (63). Further, caloric restriction or treatment 
with caloric restriction mimetics, that increase autophagy activ-
ity, enhance autophagy-dependent ATP release and improve 
MTX-induced tumor growth delay in a T cell dependent fashion 
(64).
Oppositely, a different study using a different ICD inducer 
(photo-oxidative ER stress inducer hypericin) has demonstrated 
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autophagy-independent ATP release, but observed enhanced 
surface CRT exposure when autophagy was attenuated. The 
enhanced DC maturation and IL-6 secretion further promote 
IFNγ-producing T lymphocytes (65). Interestingly, surface CRT 
exposure after MTX or hypericin treatment could be ablated in 
cells lacking lysosome-associated LAMP2A, an essential gene for 
a chaperone-mediated autophagy (66). Moreover, regarding ATP, 
it was demonstrated that extracellular residing ATP does not relay 
an immunogenic response per se (67) and further illustrates the 
context dependence of effects resulting in immunogenicity.
The involvement of autophagy-related proteins in the release 
of the DAMP HMGB1 has been demonstrated using ATG5fl/fl Cre+ 
bone marrow-derived macrophages (11) and dying glioma cancer 
cells [in which HMGB1 was found in a subset of autophagosomes 
before release (68)]. The released HMGB1 by dying cancer cells 
can bind Toll-like receptor (TLR-) 4 and promote the process-
ing and presentation of tumor antigens by DCs. This leads to 
cross-priming of T-cells and enhances immunosurveillance 
(69). Furthermore, endothelial cell exposure to HMGB1 triggers 
pro-angiogenic effects (70), including endothelial cell migration, 
sprouting and induction of an autocrine signaling cascade that 
results in elevated expression of leukocyte adhesion molecules 
ICAM-1, VCAM-1, and E-selectin. Moreover, HMGB1 induced 
expression of VEGF-A, VEGFR1, VEGFR2, and neuropilin-1 
(71) and stimulation of angiogenesis (72).
In conclusion, ICD is an important pillar of therapy-
induced antitumor immunity as it relays important signaling 
to the immune system, including DCs. DC stimulation may 
be important to induce tumor cure as demonstrated by ICD-
based DC-vaccines in high grade glioma-bearing mice (73). 
Nevertheless, the influence of autophagy on the display of 
DAMPs may be ICD-inducer dependent and requires further 
understanding for effective use.
Cytokine Release and influence on the 
Tumor Microenvironment
ATP can bind the P2RX7 receptor and activate the NOD-like 
receptor family, pyrin domain containing 3 (NLRP3) inflam-
masome in DCs and macrophages (74). This inflammasome 
activation can be suppressed by autophagy (20), which would 
be favorable as inflammasome activation and subsequent IL-1B 
release by, e.g., macrophages have pro-tumorigenic effects. 
However, the P2RX7 receptor impairs autophagy by block-
ing lysosomal function and stimulates release of vesicles with 
autophagolysosome characteristics (75). This suggests that 
activation of the P2RX7 receptor leads to a secretory phenotype, 
via inhibition of autophagy. Depletion of IL-1B arrests growth 
in melanoma (76), and macrophage-derived IL-1B-induced 
IL-17 expression from γδ T cells resulted in expansion of tumor-
associated neutrophils that suppress cytotoxic T cells in breast 
cancer, resulting in increased number of pulmonary and lymph 
node metastases (77). Alternatively, in a murine colon carcinoma 
model, autophagy-dependent ATP release after MTX treatment 
promoted recruitment of IFNγ-producing CD8+ T cells into the 
tumor in an IL-1B-mediated fashion (61).
Lipopolysaccharide/LPS  +  ATP stimulated GABARAP 
knockout macrophages to secrete more IL-1B and IL-6. In 
addition, GABARAP knockout lymphocytes produced more IL-2 
and interferon-γ. In this model, GABARAP KO was associated 
with reduced tumor incidence. These effects were validated on 
tumor control in a melanoma tumor cell-inoculated model (78) 
and indicated that GABARAP in non-cancerous cells is sufficient 
to sustain pro-tumorigenic effects potentially due to control of 
cytokine secretion.
A study using MMTV-PyMT mouse model of breast cancer 
bearing a conditional deletion of autophagy gene FIP200 shows 
that these tumor cells have a different chemokine secretion 
profile than FIP200-proficient cells. The TME polarizes toward 
an improved immunosurveillance as enhanced secretion of 
chemokines, including CXCL9, CXCL10, and CXCL11, leads 
to increased infiltration of IFNγ-producing CD8+ and CD4+ 
T cells (47).
In conclusion, autophagy-related secretion is important in 
controlling the cytokine profile of different cell types.
Prometastatic: Driving an invasive 
behavior of Cancer Cells
Oncogenic mutations in RAS are highly prevalent in cancers 
and drive different pro-tumorigenic features, including prolif-
eration, survival, and invasion. Autophagy-deficient HRASV12-
transformed breast cancer cell lines display reduced invasive 
protrusions in genetic knockdown models (including ATG7, 
ATG12, and ATG3) and after pharmacological inhibition (chlo-
roquine or bafilomycin A1). Addition of conditioned medium 
of autophagy-proficient cells rescues the invasive phenotype, 
indicating a role for autophagy-dependent secretion in triggering 
cellular migration. Correspondingly, the pulmonary metastatic 
potential of HRASV12 tumors is reduced in autophagy-deficient 
cells, effects dependent on autophagy-related secretion (55). 
Despite these results, in this model, the role of IL-6 in tumor 
progression is ambiguous in literature as both pro-tumorigenic 
(metastasis, angiogenesis, immune suppression) and antitu-
morigenic (CD8+ T cell trafficking to lymph nodes and tumors) 
effects on the TME are described (79).
Kraya et al. observed a cytokine profile that differed between 
melanoma cells with high and low autophagy activation that 
could be mimicked by introducing ATG7 knockdown in an 
autophagy high cell line. The main secretory factors the authors 
focused on, which were dependent on autophagy(-protein), are 
leukemia inhibitory factor (LIF), family with sequence similar-
ity 3 member C (FAM3C), dickkopf WNT signaling pathway 
inhibitor 3 (DKK3), and IL-8. These factors are able to promote 
metastasis via mechanisms that include MMP2 upregulation (IL-
8), epithelial to mesenchymal transition (FAM3C, DKK3, LIF), 
and promotion of angiogenesis (IL-8 and DKK3) (80).
Toll-like receptor 3 and TLR4, which are expressed on 
immune cells, including macrophages and DCs, but also a 
variety of cancer cell, can activate the release of an array of 
cytokines (81). Recently, it has been demonstrated that TLR3 
and TLR4 activation [in an LPS- or poly(I:C)-induced model] in 
lung cancer cell lines (A549 and H460) causes (1) Lys63-linked 
ubiquitynilation of TNF receptor-associated factor 6 (TRAF6) 
and (2) induced autophagy. Herein, autophagy was required 
8Keulers et al. Autosecretion in Tumor Progression
Frontiers in Oncology | www.frontiersin.org November 2016 | Volume 6 | Article 251
for TRAF6 ubiquitinylation that leads to downstream activa-
tion of NFκB and MAPK signaling and subsequent cytokine 
production. As a result, autophagy deficiency in these lung 
cancer cells reduced release of IL-6, C–C motif chemokine 
ligand (CCL)-2, and CCL-20. CCL-2 secretion is associated 
with cell migration and CCL-20 with a metastatic phenotype. 
Accordingly, autophagy deficiency impaired migratory capacity. 
IL-6 can induce VEGFA and MMP release that are associated 
with an invasive phenotype. Indeed, the invasive phenotype was 
dependent on autophagy and IL-6 and associated with VEGFA 
and MMP2 release (82).
In breast cancer, autophagy inhibition through ATG7 
or Beclin1 knockdown altered IL-6 secretion. Interestingly, 
autophagy deficiency increased IL-6 secretion by MCF7 (low 
autophagy-dependent survival) and decreased IL-6 secretion by 
MDA-MB-468 (high autophagy-dependent survival) cells. IL-6 
secretion is important for cancer stem cell (CSC) maintenance 
and is sufficient to induce CD44+:CD24low/− phenotype in 
breast cancer cells (83). In line, autophagy deficiency decreased 
mammosphere formation capacity of MDA-MB-468 cells. 
Rescue experiments illustrated that mammosphere forma-
tion was improved by IL-6 treatment and conditioned media 
from autophagy-proficient MDA-MB-468 cells. Autophagy-
dependent secretion of IL-6, but also other factors, are able to 
promote mammosphere formation and may be important in 
CSC maintenance (84).
Prometastatic: weibel–Palade body 
Formation in vascular endothelium to 
Facilitate Metastasis
Aberrant signaling in tumor-associated endothelial cells con-
tributes to excessive neovascularization that is a feature of solid 
tumors [reviewed in Ref. (72)]. As discussed above, autophagy 
is important to sustain the secretion of protein-containing 
WPB by proper vWF maturation. In tumor endothelial cells 
(TECs), these WPBs contain important secretory factors that 
can influence tumor progression. In line, P-selectin is sorted 
into WPBs as a result of its ability to interact with vWF and 
is translocated to the cell membrane upon stimulation (85). 
Once localized at the luminal side of the endothelial cell, it 
facilitates metastasis formation by promoting adhesion of 
circulating tumor cells (86). Impairment of autophagy may, 
therefore, reduce development of metastases. In addition to 
vWF and P-selectin, WPBs can contain other secretory proteins 
as angiopoietin 2 which is positively associated with tumor 
progression (due to its angiogenic potential) and interleukin 8 
which is important in tumor progression and metastasis (due 
to its angiogenic and immune response modulating potential). 
Collectively, autophagy-dependent WPB formation may facili-
tate tumor progression, although these aspects require further 
investigation.
Therapy Resistance
Autophagy has been implicated in promoting chemo- and 
radioresistance. Although often presumed to be caused by its 
degradative feature, we demonstrated in irradiated cancer cells 
that knockdown of ATG7 or LC3B, but not treatment with lyso-
somal inhibitor chloroquine, sensitizes cancer cells to radiation 
(87). This further supports a role of autophagy-related proteins 
to promote radioresistance through an alternative process 
such as secretion. For example, HMGB1 is secreted through 
autophagy-dependent mechanisms during ICD (11, 68). 
Although this factor is an important DAMP that can increase 
immunogenic responses, HMGB1 increases doxorubicin 
resistance in neighboring breast cancer cells (88). In line, the 
interaction of HMGB1 with the receptor for advanced glycation 
end products (RAGE) that is expressed on various cell lines in 
the tumor increases chemo resistance by inducing pro-survival 
autophagy (89).
In addition to increasing angiogenesis and the prometa-
static potential by DKK3, DKK3 expression is associated with 
docetaxel chemo sensitivity in lung cancer cells through 
decreasing expression of the drug efflux pump P-glycoprotein 
(90). Furthermore, DKK3 overexpression in an esophageal 
adenocarcinoma cell line was associated with increased 5-FU 
and cisplatin resistance, invasion, and activation of the TGF-B 
signaling (91).
In short, autophagy-dependent secretion is involved in 
antitumor effects through enhancing immunosurveillance, but 
is also important in tumor progression through stimulation of 
angiogenesis, changing drug resistance, triggering EMT, and 
increasing metastases development. Manipulation of the secreted 
arsenal of proteins, and tilting the balance more toward an anti-
tumor strategy may be an attractive novel approach in cancer 
treatment.
AUTOPHAGY-DePeNDeNT ReCePTOR 
TRAFFiCKiNG iN TUMOR PROGReSSiON
Autophagy execution requires cargo recognition, packaging, 
vesicle transport, vesicle fusion, and degradation. In addition to 
the catabolic function of autophagy, the autophagy machinery 
is utilized for more purposes, including intracellular trafficking 
and endocytic signaling. In addition to these roles in secretion, 
autophagy mediates the retro- and anterograde trafficking 
of membrane-bound receptors that may influence tumor 
progression.
For example, the GABARAP protein family mediates mem-
brane of cell- surface expression of receptors like the GABA (A) 
receptor (GABAAR) (92), the human kappa opioid receptor 
(hKOPR) (93), transient receptor potential cation channel sub-
family V member 1 (TRPV1) (94), the angiotensin II receptors 
(AGTR) (95, 96), and the epidermal growth factor receptor 
(EGFR) (51).
Epidermal growth factor receptor controls cell proliferation, 
migration and differentiation and is frequently overactivated in 
several cancer types due to amplification or mutation (97). EGFR 
expressing tumors depend on autophagy for their survival and 
proliferation. Inhibition of autophagy by the administration of 
chloroquine abrogated the radioresistant phenotype of these 
tumors (52) [reviewed in Ref. (98)]. Interestingly, during hypoxia, 
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translocation of EGFR to the plasma membrane is controlled 
by GABARAPL1 (51). Upon hypoxia exposure, GABARAPL1 
colocalizes with EGFR at the cytoplasmic site of the plasma 
membrane. Moreover, knockdown of GABARAPL1 resulted in a 
decrease in EGFR membrane expression, but not in overall EGFR 
expression, suggesting a role for GABARAPL1 in anterograde 
transport of EGFR.
The KOR and GABAAR are involved in neurological processes 
and play a role in a variety of processes like pain sensation, con-
sciousness, and mood.
The GABA(A) receptor (GABAAR) is well known for its inhibi-
tory role on active neurons and is expressed on the postsynaptic 
throughout the whole body, although mainly expressed in the 
mammalian brain. Surprisingly, overexpression of the GABAAR 
leads to several types of cancer including breast, liver, lung, 
and pancreatic cancers and contributes to migration of breast 
cancer cells through activation of extracellular-regulated kinase 
1/2 (ERK1/2) (99–104). GABARAP and GABARAPL1 are both 
involved in GABAAR trafficking toward the plasma membrane. 
In this role, GABARAP probably serves as a cargo-receptor which 
mediates GABAAR incorporation in the transport vesicle by a 
direct interaction with the γ2 subunit of the receptor. GABARAP-
knockdown mice show no defects in GABAAR expression, sug-
gesting that GABARAP is redundant and other molecules, like its 
homolog GABARAPL1, can take over its function (105).
In contrast to the pro-tumorigenic effects of EGFR and 
GABAAR signaling, membrane expression mediated through 
autophagy-related proteins also results in the expression of recep-
tors that may inhibit tumor progression, for example through 
KOR signaling. The KOR is well characterized for its analgesic 
role. However, the KOR also acts as a negative regulator of cell 
proliferation in breast, lung, and prostate cancers (106, 107). 
Opioid receptors belong to the GPCR family, and activation 
of the receptors modulates the MAPK pathway and inhibits 
prosurvival PI3K/AKT signaling molecules and may antagonize 
EGFR signaling (106). Both GABARAP and GABARAPL1 
are required for anterograde transport of the KOR receptor. 
Interestingly, because of its stronger interaction, GABARAPL1 
does not need C-terminal modification in contrast to GABARAP, 
which requires membrane association to transport the KOR to 
the plasma membrane (93).
Taken together, the GABARAP family proteins mediates 
trafficking and surface expression of receptors with both tumor 
promoting (EGFR, GABAAR) and tumor inhibitory characteris-
tics (KOR). This suggests that the GABARAP family contributes 
to cancer progression in a context-dependent manner, being in a 
tumor-promoting or -inhibitory role.
CONClUDiNG ReMARKS
Autophagy has been considered as an important tumor 
suppressive process for cellular homeostasis by effectuat-
ing lysosomal degradation of the cells’ toxic constituents. 
Importantly, autophagy mediates an additional cellular feature, 
the trafficking, and release of specific proteins. These effects are 
important during physiological conditions (e.g., maintaining 
a barrier for infection by mucus and lysozyme secretion and 
waste secretion), but also mediate important effects in tumor 
progression (Figure  1). The autophagy-mediated secreted 
factors may stimulate cellular proliferation via auto- and par-
acrine signaling and establish a communicative tool between 
cells that can either stimulate or limit tumor progression. 
The autophagy-mediated release of DAMPs seems to be 
ICD inducer-dependent and polarize the TME toward a less 
immunesuppressive phenotype. Alternatively, tumors are 
characterized by promoting an immunosuppressed TME by 
cytokine signaling. Furthermore, autophagy-mediated secre-
tory signaling promotes an invasive phenotype. An important 
note is that autophagy may convey direct or indirect effects on 
secretory events through formation of the mobilized vesicle, 
facilitation of anterograde trafficking or alterations in homeo-
stasis, and/or autonomous cell signaling.
In conclusion, autophagy (or autophagy-related proteins) is an 
important cellular process that is more elaborate than solemnly a 
degradative pathway. It facilitates multiple secretory events that 
can promote tumor progression by limiting immunosurveillance 
and stimulating invasiveness and angiogenesis.
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Schematic representation of autophagy-mediated secretory events that either inhibit or support tumor progression displayed here on the left (“Antitumor”) and right 
side (“Tumor supportive”), respectively. The different sources of autophagy-dependent secretory factors (bold italic) establish multiple effects on the tumor 
microenvironment (in blue boxes) by the designated factors. As such, factors that promote angiogenesis, invasion, a migratory phenotype, cancer stem cell (CSC) 
maintenance, or chemoresistance support tumor progression. Also, a reduced surface expression of calreticulin by cancer cells undergoing immunogenic cell death 
(ICD) hinders an immunogenic response. Oppositely, some factors have counteractive effects on tumor progression by improving immune cell adhesion or 
recruitment. Moreover, the “eat-me” signal ATP together with HMGB1/TLR4-mediated improved processing and presentation of tumor antigens by dendritic cells 
(DCs) promote interferon gamma (IFNγ)-producing T cells to aid antitumor immunity. The ATP/P2RX7-mediated activation of the inflammasome in macrophages 
(mφ) and DCs can have an array of effects of which the final inhibition/support of tumor progression may be context-dependent.
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